Plasma L-carnitine levels of obese and non-obese polycystic ovary syndrome patients

Journal of Obstetrics and Gynaecology

Volumn 37, Issue 4, 2017, Pages 476-479

  Celik, Fatih ^a   Kose, Mesut ^a   Yilmazer, Mehmet ^a   Köken, Gülengül N ^a   Arioz, Dagistan Tolga ^a   Kanat Pektas, Mine ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

L Carnitine; obesity; polycystic ovary syndrome

Indexed keywords

CARNITINE; ESTRADIOL; FOLLITROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; THYROTROPIN;

ADULT; AMINO ACID BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HIP CIRCUMFERENCE; HIRSUTISM; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL IRREGULARITY; MODIFIED FERRIMAN GALLWEY SCORE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; SKIN DISEASE ASSESSMENT; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; YOUNG ADULT; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; PHYSIOLOGY;

ADOLESCENT; ADULT; BODY MASS INDEX; CARNITINE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 85011308870     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443615.2016.1264375     Document Type: Article

References (23)

1. Abdali D, Samson SE, Grover AK., 2015. How effective are antioxidant supplements in obesity and diabetes? Medical Principles and Practice 24:201–215.
2. Barber TM, Dimitriadis GK, Andreou A, Franks S., 2015. Polycystic ovary syndrome:insight into pathogenesis and a common association with insulin resistance. Clinical Medicine (London) 15(Suppl 6):s72–s76.
3. Barber TM, Dimitriadis GK, Andreou A, Franks S., 2016. Polycystic ovary syndrome:insight into pathogenesis and a common association with insulin resistance. Clinical Medicine (London) 16:262–266.
4. Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M, et al. 2016. Insulin resistance in obesity and polycystic ovary syndrome:systematic review and meta-analysis of observational studies. Gynecological Endocrinology 32:343–353.
5. Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S., 2016. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. Journal of Obstetrics and Gynaecology Research 42:837–843.
6. Diamanti-Kandarakis E, Papailiou J, Palimeri S., 2006. Hyperandrogenemia:pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatric Endocrinology Reviews 3:198–204.
7. Diamanti-Kandarakis E, Dunaif A., 2012. Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications. Endocrine Research 33:981–1030.
8. El-Hattab AW, Scaglia F., 2015. Disorders of carnitine biosynthesis and transport. Molecular Genetics and Metabolism 116:107–112.
9. Evans AM, Fornasini G., 2003. Pharmacokinetics of L-carnitine. Clinical Pharmacokinectics 42:941–967.
10. Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N., 2008. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Human Reproduction 23:1602–1606.
11. Joham AE, Palomba S, Hart R., 2016. Polycystic ovary syndrome, obesity, and pregnancy. Seminars in Reproductive Medicine 34:93–101.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC., 1985. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
13. McCoin CS, Knotts TA, Adams SH., 2015. Acylcarnitines-old actors auditioning for new roles in metabolic physiology. Nature Reviews Endocrinology 11:617–625.
14. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. 2013. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism 98:E628–E637.
15. Mynatt RL., 2009. Carnitine and type 2 diabetes. Diabetes/Metabolism Research and Reviews 25(Suppl 1):S45–S49.
16. Pauli JM, Raja-Khan N, Wu X, Legro RS., 2011. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabetic Medicine 28:1445–1454.
17. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, et al. 2007. Carnitine revisited:potential use as adjunctive treatment in diabetes. Diabetologia 50:824–832.
18. Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, et al. 2009. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk:effects of acetyl-L-carnitine therapy. Hypertension 54:567–574.
19. Ruggenenti P, van der Meer IM, Remuzzi G., 2010. Oral acetyl-L-carnitine therapy and insulin resistance. Hypertension 55:e26.
20. Sirmans SM, Pate KA., 2014. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology 6:1–13.
21. Sirota I, Stein DE, Vega M, Keltz MD., 2016. Insulin resistance and β-cell function calculated by homeostasis model assessment in lean, overweight, and obese women with polycystic ovary syndrome. The Journal of Reproductive Medicine 61:3–10.
22. The Rotterdam ESHRE/ASRM-Sponsered PCOS Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
23. Yuan C, Liu X, Mao Y, Diao F, Cui Y, Liu J., 2016. Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess:a prospective study. Journal of Biomedical Research 30:197–202.